Radiopharmaceuticals; Norepinephrine; Alzheimer Disease/diagnostic imaging; Alzheimer Disease/metabolism; Animals; Brain/diagnostic imaging; Brain/metabolism; Humans; Mice; Norepinephrine/metabolism; Plaque, Amyloid/metabolism; Positron-Emission Tomography/methods; Radiopharmaceuticals/pharmacokinetics; Disease Models, Animal; Molecular Probe Techniques; μPET; AD; Molecular imaging; Mouse models; Radiology, Nuclear Medicine and Imaging; mu PET; General Medicine
Abstract :
[en] Molecular imaging aims towards the non-invasive characterization of disease-specific molecular alterations in the living organism in vivo. In that, molecular imaging opens a new dimension in our understanding of disease pathogenesis, as it allows the non-invasive determination of the dynamics of changes on the molecular level. IMAGING OF AD CHARACTERISTIC CHANGES BY microPET: The imaging technology being employed includes magnetic resonance imaging (MRI) and nuclear imaging as well as optical-based imaging technologies. These imaging modalities are employed together or alone for disease phenotyping, development of imaging-guided therapeutic strategies and in basic and translational research. In this study, we review recent investigations employing positron emission tomography and MRI for phenotyping mouse models of Alzheimer's disease by imaging. We demonstrate that imaging has an important role in the characterization of mouse models of neurodegenerative diseases.
Disciplines :
Neurology
Author, co-author :
Winkeler, A; Laboratory for Gene Therapy and Molecular Imaging, Max Planck Institute for Neurological Research, and the Faculty of Medicine, University of Cologne, Gleuelerstrasse 50, Cologne, Germany
Waerzeggers, Y; Laboratory for Gene Therapy and Molecular Imaging, Max Planck Inst. for Neurol. Res. with Klaus-Joachim-Zulch-Laboratories of the Max Planck Society, Faculty of Medicine of the University of Cologne, 50931 Cologne, Germany ; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
Klose, A; Laboratory for Gene Therapy and Molecular Imaging, Max Planck Inst. for Neurol. Res. with Klaus-Joachim-Zulch-Laboratories of the Max Planck Society, Faculty of Medicine of the University of Cologne, 50931 Cologne, Germany ; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
Monfared, P; Laboratory for Gene Therapy and Molecular Imaging, Max Planck Inst. for Neurol. Res. with Klaus-Joachim-Zulch-Laboratories of the Max Planck Society, Faculty of Medicine of the University of Cologne, 50931 Cologne, Germany ; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
Thomas, A V; Laboratory for Gene Therapy and Molecular Imaging, Max Planck Inst. for Neurol. Res. with Klaus-Joachim-Zulch-Laboratories of the Max Planck Society, Faculty of Medicine of the University of Cologne, 50931 Cologne, Germany ; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
Schubert, M; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
HENEKA, Michael ; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany ; Department of Neurology, University of Muenster, Münster, Germany
Jacobs, A H; Laboratory for Gene Therapy and Molecular Imaging, Max Planck Inst. for Neurol. Res. with Klaus-Joachim-Zulch-Laboratories of the Max Planck Society, Faculty of Medicine of the University of Cologne, 50931 Cologne, Germany ; Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany
External co-authors :
yes
Language :
English
Title :
Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's disease.
Publication date :
March 2008
Journal title :
European Journal of Nuclear Medicine and Molecular Imaging
Acknowledgements Our work is supported in part by the Deutsche Forschungsgemeinschaft (DFG-Ja98/1-2), Center for Molecular Medicine Cologne (CMMC-C5), 6th FW EU grants EMIL (LSHC-CT-2004-503569) and DiMI (LSHB-CT-2005-512146).
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986;83:4913-7.
Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004;6:1054-61.
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-7.
Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-8.
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-60.
Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1:345-7.
Higgins GA, Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav Pharmacol 2003;14:419-38.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Nat Acad Sci U S A 1997;94:13287-92.
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-7.
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-3.
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100.
Heiss WD, Graf R, Wienhard K. Relevance of experimental ischemia in cats for stroke management: a comparative reevaluation. Cerebrovasc Dis (Basel, Switzerland) 2001;11:73-81.
Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001;124:20-9.
Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001;286:2120-7.
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-8.
Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-9.
Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz MO, et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm 2000;107:1457-68.
Namba H, Fukushi K, Nagatsuka S, Iyo M, Shinotoh H, Tanada S, et al. Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. Methods 2002;27:242-50.
Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000;48:194-200.
Rinne JO, Kaasinen V, Jarvenpaa T, Nagren K, Roivainen A, Yu M, et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:113-5.
Thomas A, Klein JC, Galldiks N, Hilker R, Grond M, Jacobs AH. Multitracer PET imaging in Heidenhain variant of Creutzfeldt-Jakob disease. J Neurol 2005.
Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72.
Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurology 2002;61:797-805.
Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-8.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:RC189.
Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, et al. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2005;32:593-600.
Klunk WE, Lopresti BJ, Debnath ML, Holt DP, Wang Y, Huang G-F, et al. P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid. Neurobiol Aging 2004;25:S232-S33.
Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-606.
McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 1999;6:231-44.
Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004;101:3100-5.
Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006;26:1343-54.
